Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 4/20 | 0.52 |
| ▸ | KDR | P35968 | 3/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.46 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.46 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.46 |
| ▸ | TTBK1 | Q5TCY1 | 3/20 | 0.43 |
| ▸ | TTBK2 | Q6IQ55 | 2/20 | 0.43 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.43 |
| ▸ | RAF1 | P04049 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 1/20 | 0.41 |
| ▸ | CDK1 | P06493 | 2/20 | 0.40 |
| ▸ | TEK | Q02763 | 1/20 | 0.40 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.40 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4172506 | 0.89 | KDR (0.48) | CACNA1HKDRPDE10ACSNK1A1CSNK1D | |
| SCHEMBL4167598 | 0.89 | CDK1 (0.46) | CACNA1HKDRPDE10ACSNK1A1CSNK1D | |
| SCHEMBL4165936 | 0.88 | KDR (0.58) | CACNA1HKDRPDE10ACSNK1A1CSNK1D | |
| SCHEMBL30822929 | 0.85 | CACNA1H (0.60) | CACNA1HCACNA1GCACNA1BCACNA1C | |
| SCHEMBL5452871 | 0.84 | DYRK1A (0.56) | KDRPDE10ACSNK1A1CSNK1DGSK3B | |
| SCHEMBL4169753 | 0.80 | KDR (0.61) | KDRPDE10ACSNK1A1CSNK1DGSK3B | |
| SCHEMBL30822896 | 0.80 | CACNA1H (0.52) | CACNA1HCACNA1GCACNA1BCACNA1C | |
| SCHEMBL30822926 | 0.79 | CACNA1H (0.51) | CACNA1HCACNA1GCACNA1BCACNA1C | |
| SCHEMBL4161466 | 0.78 | KDR (0.53) | CACNA1HKDRPDE10ACSNK1A1CSNK1D | |
| SCHEMBL30822919 | 0.78 | CACNA1H (0.50) | CACNA1HCACNA1GCACNA1BCACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090082404-A1 | BENZIMIDAZOLES | MERCK PATENT GMBH (DE) | 2009-03-26 | — | — | US | claimed |
| US-20070066660-A1 | Benzimidazolyl derivatives | MERCK PATENT GMBH (DE) | 2007-03-22 | — | — | US | claimed |
| EP-1675849-A1 | BENZIMIDAZOLYL DERIVATIVES | MERCK PATENT GmbH (DE) | 2006-07-05 | — | — | EP | claimed |
| WO-2005042520-A1 | BENZIMIDAZOLYL DERIVATIVES | MERCK PATENT GMBH (DE) | 2005-05-12 | — | — | WO | claimed |
| US-20090082404-A1 | BENZIMIDAZOLES | MERCK PATENT GMBH (DE) | 2009-03-26 | — | — | US | disclosed |
| US-20090082404-A1 | BENZIMIDAZOLES | MERCK PATENT GMBH (DE) | 2009-03-26 | — | — | US | disclosed |
| US-20090082404-A1 | BENZIMIDAZOLES | MERCK PATENT GMBH (DE) | 2009-03-26 | — | — | US | disclosed |
| US-7470702-B2 | Benzimidazoles | MERCK PATENT GMBH (DE) | 2008-12-30 | — | — | US | disclosed |
| US-7470702-B2 | Benzimidazoles | MERCK PATENT GMBH (DE) | 2008-12-30 | — | — | US | disclosed |
| US-7470702-B2 | Benzimidazoles | MERCK PATENT GMBH (DE) | 2008-12-30 | — | — | US | disclosed |
| US-20070066660-A1 | Benzimidazolyl derivatives | MERCK PATENT GMBH (DE) | 2007-03-22 | — | — | US | disclosed |
| US-20070066660-A1 | Benzimidazolyl derivatives | MERCK PATENT GMBH (DE) | 2007-03-22 | — | — | US | disclosed |
| US-20070066660-A1 | Benzimidazolyl derivatives | MERCK PATENT GMBH (DE) | 2007-03-22 | — | — | US | disclosed |
| EP-1675849-A1 | BENZIMIDAZOLYL DERIVATIVES | MERCK PATENT GmbH (DE) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005042520-A1 | BENZIMIDAZOLYL DERIVATIVES | MERCK PATENT GMBH (DE) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082404-A1 | BENZIMIDAZOLES | TIE1, KDR, FLT1 | CACNA1H 3962/4885KDR 2/4885PDE10A 4225/4885 |
| US-20070066660-A1 | Benzimidazolyl derivatives | TIE1, ECE2, ABL1 | CACNA1H 4766/4885KDR 5/4885PDE10A 3571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.